Finanzas de Puma Biotechnology Inc (PBYI)PBYIPuma Biotechnology Inc

Evaluating the bottom line, Puma Biotechnology Inc maintains a gross margin of 77.92%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.42%, while the net margin is 14.49%. These profitability ratios, combined with a Return on Equity (ROE) of 21.97%, provide a clear picture of how effectively PBYI converts its operational activities into shareholder value.

In the context of the broader market, PBYI competes directly with industry leaders such as CTMX and DBVT. With a market capitalization of $507.43M, it holds a significant position in the sector. When comparing efficiency, PBYI's gross margin of 77.92% stands against CTMX's 100.00% and DBVT's 100.00%. Such benchmarking helps identify whether Puma Biotechnology Inc is trading at a premium or discount relative to its financial performance.

Puma Biotechnology has shown strong revenue growth, with Q4 2025 revenue reaching $75.45 million and a gross margin of 77.92% in Q2 2026. However, net income has fluctuated, with a loss of $3.75 million in Q1 2026, indicating volatility in profitability.